Shire PLC | |
Stock Exchange | Other OTC |
EPS |
$5.26 |
Market Cap |
$51.63 B |
Shares Outstanding |
914.55 M |
Public Float |
- |
Shire PLC ADR | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
EUR13.37 |
Market Cap |
EUR44.57 B |
Shares Outstanding |
304.85 M |
Public Float |
- |
Shire PLC | |
Stock Exchange | London Stock Exchange |
EPS |
GBP3.95 |
Market Cap |
GBP39.72 B |
Shares Outstanding |
914.55 M |
Public Float |
905.51 M |
Shire PLC | |
Stock Exchange | Mexican Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
304.85 M |
Public Float |
- |
Shire PLC ADR | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$15.98 |
Market Cap |
$51.63 B |
Shares Outstanding |
304.85 M |
Public Float |
304.8 M |
Address |
4-1-1 Dosho-machi Osaka Osaka 540 Japan |
Employees | - |
Website | http://www.takeda.co.jp |
Updated | 07/08/2019 |
Shire Plc is a biopharmaceutical company. It engaged in the research, development, licensing, manufacturing, marketing, distribution and sale of medicines to meet significant unmet patient needs. The company's products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr and foznol. |